| Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer SM Tolaney, WT Barry, CT Dang, DA Yardley, B Moy, PK Marcom, ... New England Journal of Medicine 372 (2), 134-141, 2015 | 803 | 2015 |
| Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer S Shu, CY Lin, HH He, RM Witwicki, DP Tabassum, JM Roberts, ... Nature 529 (7586), 413-417, 2016 | 597 | 2016 |
| Seven-year follow-up analysis of adjuvant paclitaxel and trastuzumab trial for node-negative, human epidermal growth factor receptor 2–positive breast cancer SM Tolaney, H Guo, S Pernas, WT Barry, DA Dillon, L Ritterhouse, ... Journal of Clinical Oncology 37 (22), 1868, 2019 | 279 | 2019 |
| Association of cell-free DNA tumor fraction and somatic copy number alterations with survival in metastatic triple-negative breast cancer DG Stover, HA Parsons, G Ha, SS Freeman, WT Barry, H Guo, ... Journal of Clinical Oncology 36 (6), 543, 2018 | 204 | 2018 |
| Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer DG Stover, CR Gil Del Alcazar, J Brock, H Guo, B Overmoyer, J Balko, ... NPJ Breast cancer 4 (1), 1-9, 2018 | 111 | 2018 |
| Phase II and Biomarker Study of Cabozantinib in Metastatic Triple‐Negative Breast Cancer Patients SM Tolaney, DR Ziehr, H Guo, MR Ng, WT Barry, MJ Higgins, SJ Isakoff, ... The Oncologist 22 (1), 25-32, 2017 | 96 | 2017 |
| Cardiac outcomes of patients receiving adjuvant weekly paclitaxel and trastuzumab for node-negative, ERBB2-positive breast cancer C Dang, H Guo, J Najita, D Yardley, K Marcom, K Albain, H Rugo, K Miller, ... JAMA oncology 2 (1), 29-36, 2016 | 84 | 2016 |
| Chemotherapy-related amenorrhea after adjuvant paclitaxel–trastuzumab (APT trial) KJ Ruddy, H Guo, W Barry, CT Dang, DA Yardley, B Moy, PK Marcom, ... Breast Cancer Research and Treatment 151 (3), 589-596, 2015 | 75 | 2015 |
| Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer AC Garrido-Castro, C Saura, R Barroso-Sousa, H Guo, E Ciruelos, ... Breast Cancer Research 22 (1), 1-13, 2020 | 71 | 2020 |
| A Meta-Analysis of the Effectiveness of Guilt on Health-Related Attitudes and Intentions Z Xu, H Guo Health Communication 33 (5), 519-525, 2017 | 71 | 2017 |
| Seven-year (yr) follow-up of adjuvant paclitaxel (T) and trastuzumab (H)(APT trial) for node-negative, HER2-positive breast cancer (BC). SM Tolaney, WT Barry, H Guo, D Dillon, CT Dang, DA Yardley, B Moy, ... Journal of Clinical Oncology 35 (15_suppl), 511-511, 2017 | 65 | 2017 |
| Using text mining to compare online pro-and anti-vaccine headlines: word usage, sentiments, and online popularity Z Xu, H Guo Communication studies 69 (1), 103-122, 2018 | 62 | 2018 |
| Phase II study of lapatinib in combination with trastuzumab in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer: clinical outcomes and … NU Lin, H Guo, JT Yap, IA Mayer, CI Falkson, TJ Hobday, EC Dees, ... Journal of Clinical Oncology 33 (24), 2623, 2015 | 59 | 2015 |
| Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer SM Tolaney, S Tan, H Guo, W Barry, EV Allen, N Wagle, J Brock, ... Investigational New Drugs, 2015 | 54 | 2015 |
| A phase II study of adjuvant paclitaxel (T) and trastuzumab (H)(APT trial) for node-negative, HER2-positive breast cancer (BC) SM Tolaney, WT Barry, CT Dang, DA Yardley, B Moy, PK Marcom, ... Cancer Research 73 (24 Supplement), S1-04-S1-04, 2013 | 52 | 2013 |
| Local–regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial) JR Bellon, H Guo, WT Barry, CT Dang, DA Yardley, B Moy, PK Marcom, ... Breast cancer research and treatment 176 (2), 303-310, 2019 | 35 | 2019 |
| Decline in left ventricular ejection fraction following anthracyclines predicts trastuzumab cardiotoxicity S Goel, J Liu, H Guo, W Barry, R Bell, B Murray, J Lynch, P Bastick, ... JACC: Heart Failure 7 (9), 795-804, 2019 | 31 | 2019 |
| Inflammatory Breast Cancer: Patterns of Failure and the Case for Aggressive Locoregional Management LEG Warren, H Guo, MM Regan, F Nakhlis, ED Yeh, HA Jacene, ... Annals of surgical oncology, 1-9, 2015 | 29 | 2015 |
| Genomic characterization of de novo metastatic breast cancer AC Garrido-Castro, LF Spurr, ME Hughes, YY Li, AD Cherniack, P Kumari, ... Clinical Cancer Research 27 (4), 1105-1118, 2021 | 27 | 2021 |
| The immune profile of small HER2-positive breast cancers: a secondary analysis from the APT trial R Barroso-Sousa, WT Barry, H Guo, D Dillon, YB Tan, K Fuhrman, ... Annals of Oncology 30 (4), 575-581, 2019 | 23 | 2019 |
